MAPT and Alzheimer disease: Low molecular weight chondroitin sulfate administration ameliorated APP metabolism, neuroinflammation, ROS production and tau protein abnormality in the brains of 5XFAD mice, displaying the potential to improve the pathological changes of AD mouse brain.